Found 55 clinical trials
Empagliflozin as a Novel Therapy in Refractory Ascites
The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients with liver cirrhosis
- 0 views
- 02 Jul, 2022
- 1 location
Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis
Decompensated liver cirrhosis is a life-threatening chronic liver disease with high mortality. Liver transplantation is the only option that can improve the survival of these patients; however, this procedure is associated with several limitations, such as the severe shortage of donor livers, long waiting lists, multiple complications, and high cost. …
- 37 views
- 07 Feb, 2022
- 1 location
Cirrhosis Care Alberta (CCAB): A Pragmatic Type II Hybrid Effectiveness Implementation Trial (CCAB)
Liver cirrhosis is the leading cause of morbidity and premature mortality in patients with digestive disease. There are many gaps in care which contribute to a high rate of hospital readmissions (44 percent at 90 days) and inadequate quality of care. Currently, there is a lack of structured processes to …
- 1 views
- 05 Jun, 2022
- 1 location
Rifamycin in Minimal Hepatic Encephalopathy
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
- 5 views
- 22 Mar, 2022
- 1 location
Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
Individuals with cirrhosis are likely to develop overt hepatic encephalopathy for which diagnostic modalities and treatment options are limited. The purpose of this study is to determine if
- 0 views
- 07 Oct, 2021
- 1 location
FMT in Cirrhosis and Hepatic Encephalopathy
Patients with end stage of liver disease or cirrhosis can develop confusion due to high ammonia and inflammation. This confusion is brought upon by changes in the bacteria in the bowels and may not respond to current standard of care treatments. Repeated episodes of confusion can make it difficult for …
- 41 views
- 05 Apr, 2022
- 1 location
VE303 for Treatment of Hepatic Encephalopathy (HE)
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy. Eligible participants will be enrolled and given oral
- 0 views
- 29 Sep, 2021
- 1 location
Deprescribing Proton Pump Inhibitors to Reduce Post-TIPS Hepatic Encephalopathy
fashion to either continue or discontinue their PPIs to determine whether these commonly used gastric acid suppressing agents increase risk of post-TIPS hepatic encephalopathy (HE). Patients will be
- 0 views
- 22 Mar, 2022
- 1 location
The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy
Through a multicenter randomized controlled trial of TIPS to prevent post-hepatitis B cirrhosis of esophagogastric varices, the incidence of hepatic encephalopathy, the rate of stent patency
- 2 views
- 15 Feb, 2022
Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF (BCAA-ACLF)
This study analyses the effect of intravenous branched chain amino acids (BCAA) on overt HE in patients with ACLF. The investigators plan to study the efficacy of combining intravenous BCAA with lactulose versus lactulose alone in the medical management of overt HE in patients with ACLF and its impact on …
- 7 views
- 24 Feb, 2022
- 1 location